ABSTRACT
AIM: To prepare genistein combined polysaccharide (GCP) liposomes and to evaluate the potential value of GCP liposomes for the treatment of prostate cancer by in vivo and in vitro experiments, and ultimately to promote the application of nanotechnology in prostate cancer chemotherapy. METHODS: GCP liposomes were prepared by ethanol injection. The anti-tumor effect of GCP liposomes was verified in vitro and in vivo by cell proliferation assay and cell cycle analysis, as well as establishing a tumor model of prostate cancer.RESULTS:GCP liposomes enhanced the inhibitory effect of GCP on androgen-sensitive LNCaP cell proliferation and the apoptosis of androgen-sensitive LNCaP cells induced by GCP. Also, GCP liposomes improved the inhibitory effect of GCP on tumor growth in tumor-bearing mice. CONCLUSION: GCP liposomes have better anti-tumor effect on androgen-sensitive human prostate cancer cells than GCP.
ABSTRACT
PURPOSE: In order to evaluate the effects of GAC, which is the combination of active hexose correlated compound (AHCC) and genistein combined polysaccharide (GCP), we investigated the changes in the biochemical profiles and the quality of life of prostate cancer patients with androgen suppression after the administration of GAC. MATERIALS AND METHODS: Thirty two eligible metastatic prostate cancer patients between the ages of 54 and 84 were enrolled in this study, and they were supplemented with 5g GAC per day (n=23) or placebo (n=9) for a 6 months period. Blood and urine sample analysis were taken and the quality of life (QoL) was assessed using the Visual Analogue Scale (VAS) and the Functional Assessment of Cancer Therapy Scale Questionnaire (FACT-G) at baseline and at post intervention (after 3 and 6 months). RESULTS: Twenty six patients (n=18 in the GAC group and n=8 in the placebo group) completed the 6 months intervention. No statistically significant adverse events were reported by the study participants. GAC had no significant effect on the serum biochemical parameters. However, all 7 GAC-treated hypercholesterolemic patients had their cholesterol level decreased after 3 months treatment (p<0.02). Results of Comet assay showed significant decreases in tail moment (p<0.009) and tail length (p<0.004) at 6 months compared to baseline for the GAC group. Although the results of the VAS were inconsistent, the score for physical well-being was increased in GAC group on the FACT-G analysis (p<0.05 between baseline and 3 months, respectively). CONCLUSIONS: Oral administration of GAC 5g per day for 6 months showed a decrease in DNA damage of blood lymphocytes and in the total serum cholesterol level in hypercholesterolemic patients without any significant influences on the serum biochemical parameters of the metastatic prostate cancer patients. Further studies on the role of GAC are necessary to clarify the advantage of GAC supplementation in prostate cancer patients with androgen suppression.